Home » Gottlieb Signals a Sea Change in FDA Risk Management Strategy, Experts Say
Gottlieb Signals a Sea Change in FDA Risk Management Strategy, Experts Say
June 23, 2006
The FDA should step back from its policy of requiring risk management plans (RMP) is part of the drug approval process,
according to a senior official — indicating a major change in the agency’s thinking on drug safety.